DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2024” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Rheumatoid Arthritis Research. Learn more about our innovative pipeline today! @ Rheumatoid Arthritis Pipeline Outlook

 

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

• In October 2024:- Eisai Korea Inc.- The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.
• In October 2024:- Sanofi- This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive.
• In October 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
• In October 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
• In October 2024:- Novartis Pharmaceuticals- A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren’s Syndrome (NEPTUNUS-1). Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren’s syndrome. The purpose of the study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly compared to placebo in patients with active Sjogren’s syndrome.
• In October 2024:- Amgen- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity. To evaluate the effect of dazodalibep on systemic manifestations of Sjögren’s Syndrome (SS) in participants with moderate-to-severe systemic disease activity.
• DelveInsight’s Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
• The leading Rheumatoid Arthritis Companies such as Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.
• Promising Rheumatoid Arthritis therapies such as BMS-582949, Imvotamab, etanercept, R-2487, and others.

 

Stay informed about the cutting-edge advancements in Rheumatoid Arthritis Treatments. Download for updates and be a part of the revolution in cancer care @ Rheumatoid Arthritis Clinical Trials Assessment

 

Rheumatoid Arthritis Emerging Drugs Profile

• SM03: SinoMab Bioscience

SM03 is a potential global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and potentially for the treatment of other immunological diseases. CD22, an inhibitory coreceptor of the BCR, is a potential immunotherapeutic target against autoimmune diseases. SM03 could disturb the CD22 homomultimeric configuration through disrupting cis binding to α2, 6-linked sialic acids, induce rapid internalization of CD22 from the cell surface of human B cells, and facilitate Trans binding between CD22 to human autologous cells. This in turn increased the activity of the downstream immunomodulatory molecule Src homology region 2 domain-containing phosphatase 1 (SHP-1) and decreased BCR-induced NF-κB activation in human B cells and B cell proliferation. This mechanism of action gives rationale to support the significant amelioration of disease and good safety profile in clinical trials, as by enabling the “self” recognition mechanism of CD22 via trans binding to α2, 6 sialic acid ligands on autologous cells, SM03 specifically restores immune tolerance of B cells to host tissues without affecting the normal B cell immune response to pathogens. In September 2023, SinoMab BioScience Limited announced that the National Medical Products Administration (NMPA) had accepted the biologics license application (BLA) for the company’s flagship product, SM03 (Suciraslimab), in the treatment of rheumatoid arthritis. Currently, the drug is been Registered for the treatment of Rheumatoid Arthritis.

• Telitacicept (RC18): RemeGen Co. Ltd.

Telitacicept is a proprietary novel fusion protein from RemeGen to treat autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-cell lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. Currently, the drug is in Preregistration stage of its development for the treatment of Rheumatoid Arthritis.

• IRL201805: Immune Regulation

IRL201805 is a first-in-class compound derived from the endogenous immuno-regulatory protein IRL201805 has demonstrated long duration of activity and disease remission with a good tolerability profile in a phase I/IIA study in patients with rheumatoid arthritis who have failed previous therapies. IRL201805 is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key player in immune function that resets the immune system for long-term disease remission. Its mechanism of action creates vast optionality across multiple indications and routes of administration. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis.

• ORYN 1001: Oryn Therapeutics

Orynotide ORYN 1001 is being developed as a novel treatment for rheumatoid arthritis, COVID-19, and other systemic inflammatory diseases. With the successful completion of Phase IB trial for the treatment of Rheumatoid Arthritis (A Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD 1 in Rheumatoid Arthritis Patients with Mild Disease Managed with DMARDs), the systemic safety profile of the first Orynotide therapeutic drug candidate has been validated. Currently, the drug is in Phase I/II stage of its development for the treatment of Rheumatoid Arthritis

 

Learn more about Rheumatoid Arthritis Drugs opportunities in our groundbreaking Rheumatoid Arthritis Research and development projects @ Rheumatoid Arthritis Unmet Needs

 

Rheumatoid Arthritis Companies

Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.

 

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Discover the latest advancements in Rheumatoid Arthritis Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Rheumatoid Arthritis Market Drivers and Barriers, and Future Perspectives

 

 Scope of the Rheumatoid Arthritis Pipeline Report

• Coverage- Global
• Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Rheumatoid Arthritis Companies- Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.
• Rheumatoid Arthritis Therapies- BMS-582949, Imvotamab, etanercept, R-2487, and others.

 

For a detailed overview of our latest research findings and future plans, read the full details of Rheumatoid Arthritis Pipeline on our website @ Rheumatoid Arthritis Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Rheumatoid Arthritis : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SM03: SinoMab
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABBV-3373: Abbvie
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SVT 6A4710: Servatus Biopharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. SYN060: Synermore Biologics Co., Ltd.
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. CABA-201: Cabaletta Bio
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Rheumatoid Arthritis – Collaborations Assessment- Licensing / Partnering / Funding
24. Rheumatoid Arthritis – Unmet Needs
25. Rheumatoid Arthritis – Market Drivers and Barriers
26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/